Calcitonin (Calcitonin, Eel)

Subscribe to Selected New Research on Calcitonin

4159 relevant articles (171 outcomes, 418 trials/studies) found for this Drug

Description: A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.

Also Known As:

Calcitonin, Eel; Calcitonin(1-32); Calcitrin; Ciba 47175-BA; Eel Calcitonin; Ciba 47175 BA; Ciba 47175BA; Thyrocalcitonin

Relationship Network

Drug Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists

Amino Acids, Peptides, and Proteins

Peptides: 16375

Experts

1.	Becker, K L: 10 articles (04/2004 - 04/2000)
2.	Snider, R H: 9 articles (04/2004 - 09/2000)
3.	White, J C: 7 articles (04/2004 - 09/2000)
4.	Nas, Kemal: 5 articles (07/2005 - 01/2002)
5.	Cevik, Remzi: 5 articles (07/2005 - 01/2002)
6.	Müller, B: 5 articles (04/2004 - 04/2000)
7.	Iczkowski, Kenneth A: 4 articles (01/2008 - 05/2005)
8.	Thomas, Shibu: 4 articles (08/2006 - 11/2005)
9.	Nylén, E S: 4 articles (04/2004 - 01/2001)
10.	Dralle, H: 4 articles (01/2004 - 04/2000)

Related Diseases

1.	Osteoporosis 09/01/1994 - "Drugs that inhibit bone turnover, such as calcitonin, appear to be effective in increasing bone mass for 1.5 to 2 years, about the time it would take to replenish the remodeling space in a patient with high turnover osteoporosis. " 10/01/1987 - "This type of treatment regime, with its calcitonin-like effect, might be effective in reducing net bone loss due to imbalance between bone formation and resorption at the BMU level, particularly in patients with increased numbers of BMUs ('high turnover' osteoporosis).(ABSTRACT TRUNCATED AT 250 WORDS)" 11/01/1999 - "These results suggest that the therapeutic efficacy of BPs or calcitonin in diseases such as glucocorticoid-induced osteoporosis may be due, in part, to their ability to prevent osteocyte and osteoblast apoptosis." 06/07/1992 - "Intermittent administration of low-dose calcitonin, especially together with an anabolic steroid seems to be a safe and effective therapy in established osteoporosis." 01/01/2000 - "Efficacy of calcitonin for fracture prevention in steroid-induced osteoporosis remains to be established." Order ALL the reference details at left...
2.	Pain (Aches) 01/01/1982 - "One week after commencing therapy there was improvement or marked improvement of pain in significantly more patients in the calcitonin group (5/13) than in the placebo group (0/12) (Fisher's exact two-tailed probability test, P = 0.0484). " 10/01/2005 - "The combined results from five randomized controlled trials, involving 246 patients, determined that calcitonin significantly reduced the severity of pain using a visual analogue scale following diagnosis. " 04/01/2003 - "Thirteen of these studies demonstrated statistically significant improvement in pain or function in calcitonin-treated patients. " 07/01/2001 - "Calcitonin is also beneficial in reducing the bone pain associated with fractures." 01/01/1986 - "In the 22 patients treated with calcitonin a significant reduction ( p less than 0.001) was observed in the severity of bone pain. " Order ALL the reference details at left...
3.	Hypercalcemia (Milk Alkali Syndrome) 02/01/1970 - "Importance of endogenous thyrocalcitonin for protection against hypercalcemia in the rat." 01/01/2006 - "The conflicting results of previous evaluations of the influence of hypercalcemia on thyroid C-cells and the absence of reports on its influence on calcitonin (CT)-producing cells of the airways prompted this study. " 01/01/1979 - "Studies of calcitonin cells and parathyroid gland of house shrew, Suncus murinus in response to experimental hypercalcemia." 01/01/1979 - "A study of the action of calcitonin by its effects on lead-induced hypercalcemia." 10/01/2009 - "In addition, C(+)P(+) and C(+)P(-), but not C(-)P(-), mice showed increases in serum calcitonin (CT) levels during hypercalcemia. " Order ALL the reference details at left...
4.	Neoplasms (Cancer) 01/01/1990 - "Progress in the knowledge of the disease has recently been obtained in the following ways: the IRMA assay of mature calcitonin, the disease marker, has permitted earlier diagnosis of familial cases and recurrence; the locus assignment of the gene on chromosome 10 now enables a valid discrimination in certain families of gene carriers; collaborative clinical, biological, pathological, therapeutic and epidemiological research on a nation-wide scale has had a beneficial effect on patients, with improvement in diagnosis of the familial forms, in disease prognosis, in cancer detection at an infraclinical stage, and in the regrouping and distribution of families in France." 03/01/2007 - "Tissue-specific expression of the promoter for calcitonin and calcitonin-related polypeptide alpha has allowed therapeutic genes to be specifically expressed in calcitonin-secreting cells and in the MTC tumors derived from them; such tissue-specific expression contributes to improved safety of gene therapies and has the potential to increase their therapeutic index. " 08/01/1995 - "We have measured SRIF plasma levels in 35 patients with different stages of MTC to evaluate the use of SRIF as a plasma tumor marker compared to the current "gold standard" calcitonin (CT). " 07/01/2007 - "In this study, we propose calcitonin measurement in the washout of FNAB needles after sampling each tumor (FNAB-CT) as a new approach to diagnosis of MTC. " 01/01/2007 - "In addition to RET, an old marker, calcitonin, has assumed increasing importance, but may not adequately reflect changes in tumor burden in RET inhibitor trials. " Order ALL the reference details at left...
5.	Postmenopausal Osteoporosis 03/28/1981 - " Calcitonin may prove effective in the prevention of postmenopausal bone loss. " 01/01/2000 - "Studies 4 and 5 assessed the efficacy of the combined therapy of HRT and calcitonin in the prevention of early postmenopausal bone loss. " 07/01/1993 - "Ongoing studies are evaluating the efficacy of intranasal calcitonin and of biphosphonates for the prevention of postmenopausal osteoporosis. " 01/01/2004 - "The European Union's regulatory authority, the Committee for Proprietary Medicinal Products (CPMP), has confirmed the efficacy of calcitonin formulations for the treatment of postmenopausal osteoporosis and other bone disorders. " 10/01/1998 - "A total of 107 patients were included in the study to determine the effects of different doses of intranasal calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Calcium
2.	Diphosphonates
3.	pamidronate (APD)
4.	Parathyroid Hormone (Parathormone)
5.	Alendronate (Alendronate Sodium)
6.	Estrogens (Estrogen)
7.	Etidronic Acid (HEDP)
8.	Vitamin D
9.	Adrenocorticotropic Hormone (ACTH)
10.	Pentagastrin (Peptavlon)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Thyroidectomy
3.	Intralesional Injections
4.	Ovariectomy (Oophorectomy)
5.	Transplants (Transplant)

Best Treatments:
Research Summary Report
on Osteoporosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 888 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>